HUE030409T2 - Orodispersible desmopressin preparation to increase the length of the initial period of sleep disturbed by nocturia - Google Patents
Orodispersible desmopressin preparation to increase the length of the initial period of sleep disturbed by nocturia Download PDFInfo
- Publication number
- HUE030409T2 HUE030409T2 HUE13181216A HUE13181216A HUE030409T2 HU E030409 T2 HUE030409 T2 HU E030409T2 HU E13181216 A HUE13181216 A HU E13181216A HU E13181216 A HUE13181216 A HU E13181216A HU E030409 T2 HUE030409 T2 HU E030409T2
- Authority
- HU
- Hungary
- Prior art keywords
- patient
- dose
- nocturnal
- desmopressin
- baseline
- Prior art date
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title claims abstract description 91
- 229960004281 desmopressin Drugs 0.000 title claims abstract description 79
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title claims abstract description 79
- 230000007958 sleep Effects 0.000 title claims description 45
- 206010029446 nocturia Diseases 0.000 title abstract description 64
- 238000011282 treatment Methods 0.000 claims abstract description 74
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 230000000422 nocturnal effect Effects 0.000 claims description 106
- 210000002966 serum Anatomy 0.000 claims description 24
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 claims description 13
- 229960002845 desmopressin acetate Drugs 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000002485 urinary effect Effects 0.000 claims description 7
- 239000002585 base Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 1
- 239000000645 desinfectant Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 description 78
- 229940068196 placebo Drugs 0.000 description 57
- 239000000902 placebo Substances 0.000 description 57
- 230000007423 decrease Effects 0.000 description 51
- 230000008859 change Effects 0.000 description 45
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 28
- 229910052708 sodium Inorganic materials 0.000 description 28
- 239000011734 sodium Substances 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 25
- 230000009467 reduction Effects 0.000 description 20
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 14
- 238000012544 monitoring process Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 206010021036 Hyponatraemia Diseases 0.000 description 10
- 230000036033 hyponatraemia Effects 0.000 description 10
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000011800 void material Substances 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 7
- 230000004622 sleep time Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 101800001144 Arg-vasopressin Proteins 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000004617 sleep duration Effects 0.000 description 5
- 230000003860 sleep quality Effects 0.000 description 5
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 4
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 4
- 230000002686 anti-diuretic effect Effects 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 230000002060 circadian Effects 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 238000001134 F-test Methods 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000005346 nocturnal enuresis Diseases 0.000 description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 206010059240 Lymphostasis Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010034268 Pelvic prolapse Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Chemical group 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5512008P | 2008-05-21 | 2008-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE030409T2 true HUE030409T2 (en) | 2017-05-29 |
Family
ID=41100519
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13181216A HUE030409T2 (en) | 2008-05-21 | 2009-05-21 | Orodispersible desmopressin preparation to increase the length of the initial period of sleep disturbed by nocturia |
| HUE16165875A HUE039013T4 (hu) | 2008-05-21 | 2009-05-21 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
| HUE17171152A HUE041370T2 (hu) | 2008-05-21 | 2009-05-21 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
| HUE17171155A HUE046050T2 (hu) | 2008-05-21 | 2009-05-21 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
| HUS1900024C HUS1900024I1 (hu) | 2008-05-21 | 2019-04-26 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16165875A HUE039013T4 (hu) | 2008-05-21 | 2009-05-21 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
| HUE17171152A HUE041370T2 (hu) | 2008-05-21 | 2009-05-21 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
| HUE17171155A HUE046050T2 (hu) | 2008-05-21 | 2009-05-21 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
| HUS1900024C HUS1900024I1 (hu) | 2008-05-21 | 2019-04-26 | Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9974826B2 (OSRAM) |
| EP (5) | EP2712622B1 (OSRAM) |
| JP (5) | JP5767103B2 (OSRAM) |
| CA (1) | CA2724653A1 (OSRAM) |
| DK (5) | DK2296686T4 (OSRAM) |
| ES (5) | ES2710454T3 (OSRAM) |
| HR (4) | HRP20161066T1 (OSRAM) |
| HU (5) | HUE030409T2 (OSRAM) |
| LT (5) | LT2712622T (OSRAM) |
| LU (1) | LUC00015I2 (OSRAM) |
| NO (3) | NO3085381T3 (OSRAM) |
| PL (5) | PL2712622T3 (OSRAM) |
| PT (5) | PT3085381T (OSRAM) |
| SI (4) | SI3085381T1 (OSRAM) |
| TR (2) | TR201807224T4 (OSRAM) |
| WO (1) | WO2009143356A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100286045A1 (en) * | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| NO3085381T3 (OSRAM) * | 2008-05-21 | 2018-09-15 | ||
| WO2015063602A1 (en) * | 2013-10-29 | 2015-05-07 | Ferring B.V. | Desmopressin and blood glucose |
| EP3868215A4 (en) * | 2018-10-16 | 2022-07-27 | Nippon Chemiphar Co., Ltd. | SLEEP QUALITY IMPROVING AGENT |
| KR20210078500A (ko) * | 2018-10-17 | 2021-06-28 | 닛뽕 케미파 가부시키가이샤 | 야간 다뇨의 치료 또는 예방제 |
| US20230149330A1 (en) * | 2020-04-14 | 2023-05-18 | Nippon Chemiphar Co., Ltd. | Sleep quality improver |
| CA3198547A1 (en) | 2020-11-16 | 2022-05-19 | Mark RIDALL | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4285858A (en) * | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
| US4263283A (en) * | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
| GB2111423B (en) | 1981-12-02 | 1985-06-26 | Wyeth John & Brother Ltd | Making quick-dissolving pills |
| DE3275121D1 (en) | 1981-12-11 | 1987-02-19 | Wyeth John & Brother Ltd | Process for preparing solid shaped articles |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4878892A (en) | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| DK365389D0 (da) | 1989-07-24 | 1989-07-24 | Fertin Lab As | Antifungalt tyggegummipraeparat |
| US5091186A (en) * | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
| TW279133B (OSRAM) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9101022D0 (sv) * | 1991-01-09 | 1991-04-08 | Paal Svedman | Medicinsk suganordning |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| IL102857A (en) | 1991-08-26 | 1997-02-18 | Abbott Lab | Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration |
| NZ246091A (en) | 1991-12-24 | 1995-08-28 | Yamanouchi Pharma Co Ltd | Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol |
| US5298256A (en) * | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5343672A (en) | 1992-12-01 | 1994-09-06 | Scherer Ltd R P | Method for manufacturing freeze dried dosages in a multilaminate blister pack |
| CA2090738C (en) | 1993-02-24 | 1996-05-21 | Hema-Quebec | Use of paf |
| SE9300937L (sv) * | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| US5434121A (en) * | 1993-03-25 | 1995-07-18 | Mitsui Toatsu Chemicals, Incorporated | Variety of Drechslera monoceras, weed control compositions containing the same as an effective ingredient and weed control methods using the same |
| SE501677C2 (sv) | 1993-06-18 | 1995-04-10 | Ferring Bv | Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel |
| US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
| US5674850A (en) | 1993-12-23 | 1997-10-07 | Ferring Ab | High purity desmopressin produced in large single batches |
| EP0710243B1 (en) * | 1993-06-29 | 2000-06-14 | Ferring B.V. | Synthesis of cyclic peptides |
| DE69427820T2 (de) | 1993-06-29 | 2001-11-08 | Ferring B.V., Hoofdorp | Zusammensetzungen zur nasalen verabreichung von desmopressin |
| US5500413A (en) * | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
| US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5707648A (en) * | 1993-11-17 | 1998-01-13 | Lds Technologies, Inc. | Transparent liquid for encapsulated drug delivery |
| SE9400918L (sv) * | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| JP2551742B2 (ja) * | 1994-05-23 | 1996-11-06 | 三星電機株式会社 | 医薬品投与用皮膚傷形成装置 |
| DE4424800A1 (de) * | 1994-07-14 | 1996-01-18 | Philips Patentverwaltung | Schaltungsanordnung zum Liefern von Speisespannungen |
| SE518619C2 (sv) * | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Komposition för reglerad frisättning innehållande monokaproin |
| GB9502879D0 (en) * | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| IL113459A (en) * | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
| US5843016A (en) | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
| TW411277B (en) | 1996-05-13 | 2000-11-11 | Hisamitsu Pharmaceutical Co | Percutaneous tape preparation containing fentanyl |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| DE69719761T2 (de) * | 1996-06-18 | 2003-12-18 | Alza Corp., Palo Alto | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
| US5763398A (en) * | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| US5922680A (en) * | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| FR2758195B1 (fr) | 1997-01-09 | 1999-02-26 | Sgs Thomson Microelectronics | Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US6194407B1 (en) * | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
| US5932745A (en) * | 1997-07-30 | 1999-08-03 | American Home Products Corporation | Process for converting propargylic amine-N-oxides to enaminones |
| US6511974B1 (en) * | 1997-07-30 | 2003-01-28 | Wyeth | Tricyclic vasopressin agonists |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
| US6090803A (en) * | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
| US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| GB9827292D0 (en) | 1998-12-12 | 1999-02-03 | Univ Strathclyde | Freeze drying |
| US6406455B1 (en) * | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| US6235900B1 (en) * | 1999-02-04 | 2001-05-22 | American Home Products Corporation | Tricyclic pyridine N-oxides vasopressin agonists |
| US6620807B1 (en) | 1999-02-04 | 2003-09-16 | Wyeth | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| US6297234B1 (en) | 1999-02-04 | 2001-10-02 | American Home Products Corporation | Arylthiophene vasopressin agonists |
| US6344451B1 (en) * | 1999-02-04 | 2002-02-05 | American Home Products | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| JP4435424B2 (ja) | 1999-02-15 | 2010-03-17 | 大日本住友製薬株式会社 | 口腔内で速やかに崩壊する錠剤 |
| JP2002537031A (ja) * | 1999-02-18 | 2002-11-05 | バイオバルブ テクノロジーズ インコーポレイテッド | 電気活性な細孔 |
| AR014640A1 (es) * | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| EP1296730B2 (en) | 2000-01-07 | 2014-07-30 | Valeritas, Inc. | Injection device |
| US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| EP1333880B1 (en) | 2000-10-26 | 2009-04-15 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| WO2002055128A2 (en) * | 2000-11-30 | 2002-07-18 | Biovalve Technologies Inc | Fluid delivery and measurement systems and methods |
| EP1339442A4 (en) | 2000-11-30 | 2006-12-27 | Biovalve Technologies Inc | INJECTION SYSTEMS |
| WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| WO2002050584A2 (en) * | 2000-12-21 | 2002-06-27 | Biovalve Technologies, Inc. | Microneedle array systems |
| PT1381352E (pt) | 2001-03-16 | 2007-07-27 | Alza Corp | Adesivo transdérmico para administração de fenantil |
| US7022699B2 (en) * | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| DK1381370T3 (da) * | 2001-04-12 | 2007-05-21 | Wyeth Corp | N-Biphenylcarbonyl- og N-phenylpyridylcarbonyl-substituerede bi- og tricykliske azepiner og diazepiner som vasopressin-agonister |
| DK1381608T3 (da) * | 2001-04-12 | 2008-02-04 | Wyeth Corp | Cyclohexylphenylvasopressinagonister |
| GB2391480B (en) * | 2002-08-05 | 2007-02-28 | Caretek Medical Ltd | Drug delivery system |
| US7615234B2 (en) * | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
| HRP20040250A2 (en) | 2001-09-13 | 2005-02-28 | Kissei Pharmaceutical Co.Ltd. | Crystals of hydroxynorephedrine derivative |
| US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| US6893655B2 (en) * | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| CA2464069A1 (en) * | 2001-11-16 | 2003-05-22 | Hiroyuki Koshio | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| WO2003094886A2 (en) | 2002-05-07 | 2003-11-20 | Ferring Bv | Desmopressin in an orodispersible dosage form |
| US6945952B2 (en) * | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| EP1590033A2 (en) * | 2002-09-30 | 2005-11-02 | Alza Corporation | Drug delivery device having coated microprojections incorporating vasoconstrictors |
| BR0314754A (pt) * | 2002-10-09 | 2005-07-26 | Toray Industries | Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica |
| US7383084B2 (en) * | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| DE10259934B3 (de) * | 2002-12-20 | 2004-10-14 | H.C. Starck Gmbh | Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| US7183271B2 (en) * | 2003-04-28 | 2007-02-27 | Astellas Pharma Inc. | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof |
| US20060193825A1 (en) * | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7094545B2 (en) * | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| WO2005004729A1 (en) | 2003-06-30 | 2005-01-20 | Alza Corporation | Method for coating skin piercing microprojections |
| PT1500390E (pt) * | 2003-07-25 | 2005-10-31 | Ferring Bv | Composicao farmaceutica como forma de dosagem solida e metodo de producao |
| CN1826099B (zh) | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| US6930932B2 (en) * | 2003-08-27 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Data signal reception latch control using clock aligned relative to strobe signal |
| JP2007508914A (ja) | 2003-10-24 | 2007-04-12 | アルザ・コーポレーシヨン | 経皮薬剤送達を促進するための装置及び方法 |
| US20050106226A1 (en) * | 2003-10-24 | 2005-05-19 | Cormier Michel J. | Pretreatment method and system for enhancing transdermal drug delivery |
| EP1680154B1 (en) * | 2003-10-31 | 2012-01-04 | ALZA Corporation | Self-actuating applicator for microprojection array |
| JP5596252B2 (ja) * | 2003-11-10 | 2014-09-24 | アラーガン、インコーポレイテッド | 低用量デスモプレシンを含有する医薬組成物 |
| DE60305043T2 (de) | 2003-11-13 | 2006-11-30 | Ferring B.V. | Blisterverpackung und feste Dosierungsform enthaltend Desmopressin |
| EP1550439B1 (en) | 2003-12-29 | 2006-03-08 | Ferring B.V. | Method for preparing a solid dosage form of desmopressin |
| US7018653B2 (en) * | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| MXPA06007832A (es) * | 2004-01-09 | 2007-01-26 | Johnson & Johnson | Metodo y sistema de suministro de agente transdermico asistido por frecuencia. |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US7097776B2 (en) * | 2004-10-22 | 2006-08-29 | Hewlett-Packard Development Company, L.P. | Method of fabricating microneedles |
| US20060093658A1 (en) * | 2004-10-26 | 2006-05-04 | Gayatri Sathyan | Apparatus and method for transdermal delivery of desmopressin |
| CN100339081C (zh) | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| US7180274B2 (en) * | 2004-12-10 | 2007-02-20 | Aimtron Technology Corp. | Switching voltage regulator operating without a discontinuous mode |
| CA2604759A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| US7856263B2 (en) | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
| KR20080009295A (ko) | 2005-04-22 | 2008-01-28 | 와이어쓰 | 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도 |
| TW200716595A (en) | 2005-04-22 | 2007-05-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| US7368477B2 (en) | 2005-04-22 | 2008-05-06 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
| MX2007013064A (es) | 2005-04-24 | 2008-01-16 | Wyeth Corp | Metodo para modular la funcion de la vejiga. |
| CA2612005C (en) | 2005-06-17 | 2013-10-29 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
| US20080195035A1 (en) | 2005-06-24 | 2008-08-14 | Frederickson Franklyn L | Collapsible Patch and Method of Application |
| WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| WO2007098945A2 (en) | 2006-03-02 | 2007-09-07 | Ferring International Center S.A. | Stable solid dosage form comprising desmopressin |
| WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
| AU2008283929B2 (en) | 2007-08-06 | 2013-10-10 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| NO3085381T3 (OSRAM) * | 2008-05-21 | 2018-09-15 |
-
2009
- 2009-05-21 NO NO16165875A patent/NO3085381T3/no unknown
- 2009-05-21 ES ES17171152T patent/ES2710454T3/es active Active
- 2009-05-21 HU HUE13181216A patent/HUE030409T2/en unknown
- 2009-05-21 US US12/469,801 patent/US9974826B2/en active Active
- 2009-05-21 EP EP13181216.6A patent/EP2712622B1/en active Active
- 2009-05-21 SI SI200931838T patent/SI3085381T1/en unknown
- 2009-05-21 EP EP17171155.9A patent/EP3225250B1/en active Active
- 2009-05-21 ES ES17171155T patent/ES2756706T3/es active Active
- 2009-05-21 ES ES16165875.2T patent/ES2677548T3/es active Active
- 2009-05-21 LT LTEP13181216.6T patent/LT2712622T/lt unknown
- 2009-05-21 CA CA2724653A patent/CA2724653A1/en not_active Abandoned
- 2009-05-21 HU HUE16165875A patent/HUE039013T4/hu unknown
- 2009-05-21 PT PT161658752T patent/PT3085381T/pt unknown
- 2009-05-21 PT PT17171152T patent/PT3225249T/pt unknown
- 2009-05-21 DK DK09751584.5T patent/DK2296686T4/en active
- 2009-05-21 PL PL13181216T patent/PL2712622T3/pl unknown
- 2009-05-21 ES ES09751584.5T patent/ES2462465T5/es active Active
- 2009-05-21 NO NO09751584A patent/NO2296686T3/no unknown
- 2009-05-21 DK DK13181216.6T patent/DK2712622T3/en active
- 2009-05-21 WO PCT/US2009/044860 patent/WO2009143356A1/en not_active Ceased
- 2009-05-21 DK DK17171155T patent/DK3225250T3/da active
- 2009-05-21 HU HUE17171152A patent/HUE041370T2/hu unknown
- 2009-05-21 PT PT97515845T patent/PT2296686E/pt unknown
- 2009-05-21 LT LT17171155T patent/LT3225250T/lt unknown
- 2009-05-21 HU HUE17171155A patent/HUE046050T2/hu unknown
- 2009-05-21 EP EP17171152.6A patent/EP3225249B1/en active Active
- 2009-05-21 DK DK16165875.2T patent/DK3085381T3/en active
- 2009-05-21 EP EP16165875.2A patent/EP3085381B1/en active Active
- 2009-05-21 LT LTEP16165875.2T patent/LT3085381T/lt unknown
- 2009-05-21 PT PT171711559T patent/PT3225250T/pt unknown
- 2009-05-21 ES ES13181216.6T patent/ES2596435T3/es active Active
- 2009-05-21 DK DK17171152.6T patent/DK3225249T3/en active
- 2009-05-21 TR TR2018/07224T patent/TR201807224T4/tr unknown
- 2009-05-21 SI SI200931494A patent/SI2712622T1/sl unknown
- 2009-05-21 SI SI200932000T patent/SI3225250T1/sl unknown
- 2009-05-21 PL PL09751584T patent/PL2296686T5/pl unknown
- 2009-05-21 PT PT131812166T patent/PT2712622T/pt unknown
- 2009-05-21 PL PL17171155T patent/PL3225250T3/pl unknown
- 2009-05-21 PL PL17171152T patent/PL3225249T3/pl unknown
- 2009-05-21 PL PL16165875T patent/PL3085381T3/pl unknown
- 2009-05-21 SI SI200931912T patent/SI3225249T1/sl unknown
- 2009-05-21 JP JP2011510705A patent/JP5767103B2/ja active Active
- 2009-05-21 TR TR2018/19189T patent/TR201819189T4/tr unknown
- 2009-05-21 LT LTEP17171152.6T patent/LT3225249T/lt unknown
- 2009-05-21 EP EP09751584.5A patent/EP2296686B2/en active Active
-
2015
- 2015-03-31 JP JP2015072698A patent/JP6001121B2/ja active Active
-
2016
- 2016-08-22 HR HRP20161066TT patent/HRP20161066T1/hr unknown
- 2016-08-31 JP JP2016169163A patent/JP6258424B2/ja active Active
-
2017
- 2017-01-20 LT LTPA2017001C patent/LTC2712622I2/lt unknown
- 2017-04-12 LU LU00015C patent/LUC00015I2/fr unknown
- 2017-12-06 JP JP2017234382A patent/JP6506821B2/ja active Active
-
2018
- 2018-01-26 US US15/880,697 patent/US20180250357A1/en not_active Abandoned
- 2018-05-17 HR HRP20180774TT patent/HRP20180774T1/hr unknown
-
2019
- 2019-01-18 HR HRP20190114TT patent/HRP20190114T1/hr unknown
- 2019-03-29 JP JP2019067813A patent/JP6836618B2/ja active Active
- 2019-04-26 HU HUS1900024C patent/HUS1900024I1/hu unknown
- 2019-04-30 NO NO2019021C patent/NO2019021I1/no unknown
- 2019-10-14 HR HRP20191854TT patent/HRP20191854T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11020448B2 (en) | Methods comprising desmopressin | |
| US20180250357A1 (en) | Methods comprising desmopressin | |
| US11963995B2 (en) | Methods comprising desmopressin | |
| HK40002265A (en) | Desmopressin for reducing nocturnal voids | |
| HK1236847B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1238572A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1238572B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1236847A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1196253A (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1196253B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1228266B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1228266A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1216298B (en) | Desmopressin for reducing nocturnal voids | |
| HK1179156B (en) | Desmopressin for reducing nocturnal voids |